NASDAQ: RLAY
Relay Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$2.78B
52w High
$17.47
52w Low
$3.03
P/E
-10.47
Volume
7.47M
Outstanding Shares
175.02M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 372.62% over the last year. Revenue grew 39.04% over the trailing twelve months. Operating margin moved from -4,778.93% to -2,776.61%. Free cash flow grew 21.73% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum. The operating data is doing enough work that the move does not need an overvaluation story to explain it.
What would invalidate this read
Operating margin is at -2,776.61%. Revenue grew 39.04% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
15
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 6, 2026
Q3 FY26 · EPS est -$0.41 · Revenue est $733.33K
View